A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
The study aims to compare and assess the dose response of 3 selected doses of maridebart cafraglutide compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or obesity without diabetes mellitus (Cohort A) and in participants with overweight or obesity with Type 2 diabetes mellitus (Cohort B).
Inclusion Criteria:
Exclusion Criteria:
Shatin, New Territories, Hong Kong
Hashima-gun, Gifu 501-6061, Japan
Aki-gun, Hiroshima 735-8585, Japan
Kashiwara-shi, Osaka 582-0005, Japan
Chuo-ku, Tokyo 103-0025, Japan
Shibuya-ku, Tokyo 151-0051, Japan
Goyang-si, Gyeonggi-do, 10326, South Korea
Seongnam-si, Gyeonggi-do, 13620, South Korea